Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02030457 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults

A Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.

Completed
Registry status
Phase 1
Development phase
72
Enrollment target

NCT02030457 is a Phase 1 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 72 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02030457, a Phase 1 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.

COMPLETED
Registry status
Phase 1
Development phase
72 participants
Enrollment target

Study Summary

This study is designed to compare the systemic exposure of orally inhaled beclomethasone dipropionate inhalation aerosol delivered via BAI to that delivered via MDI.

Interventions

  • DRUG Beclomethasone dipropionate BAI
  • DRUG Beclomethasone dipropionate MDI

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2013-12
Est. Completion 2014-06
Phase Phase 1

What the Registry Record Tells You About NCT02030457

The ClinicalTrials.gov registry entry for NCT02030457 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Beclomethasone dipropionate BAI is the first listed.

NCT02030457 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02030457 about?

NCT02030457 is a clinical study titled "A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults". This study is designed to compare the systemic exposure of orally inhaled beclomethasone dipropionate inhalation aerosol delivered via BAI to that delivered via MDI.

What is the current status of trial NCT02030457?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2013-12. Estimated completion is 2014-06.

What interventions are being tested in trial NCT02030457?

The interventions under investigation include: Beclomethasone dipropionate BAI (DRUG), Beclomethasone dipropionate MDI (DRUG).

Who is sponsoring clinical trial NCT02030457?

This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.